Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

743 Features
Rituxan approval to mark a new era of B-cell targeted therapies of autoimmune disease?

01 Mar 06

Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
LeadDiscovery

An Interview with Andrew Copestake Vice President - BD Europe

28 Feb 06

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
Mike Wood

Abbott - Planning to Win

24 Feb 06

A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability.
Caroline Johnson

Abbott - Pipeline going from strength to strength

24 Feb 06

Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the United States – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it?
Caroline Johnson

Abbott - Global Citizenship

24 Feb 06

In an increasingly complex world, with significant changes taking place on a social, commercial and economic basis almost weekly, corporate social responsibility is a priority for Abbott as it engages its stakeholders, advances its core objectives and exercises its influence – making productive contribution to the societies and communities it operates in.
Caroline Johnson

NK1 receptor antagonists by Roche

23 Feb 06

In their study due to be published in the March edition of Bioorg Med Chem Lett, Hoffmann and colleagues from Roche describe the design of two promising NK1 receptor antagonists, netupitant and befetupitant.
LeadDiscovery

A novel therapeutic candidate for the treatment of lymphomas and other cancers

21 Feb 06

Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
LeadDiscovery

Gleevec: Improving it utility in exisiting indications; development for extended indications

10 Feb 06

The approval of Novartis’ Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartis’ second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
LeadDiscovery

Ghrelin moves back into the limelight of obesity R&D

09 Feb 06

The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitor’s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Obesity is an active area of R&D and numerous novel molecular targets are currently being evaluated. One target, ghrelin was the subject of a major target discovery report from LeadDiscovery published in 2003 Ghrelin: Pharmaceutical & Ther
LeadDiscovery

Flower power & Oncology

03 Feb 06

The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi
LeadDiscovery

Replidyne marches on in the development of novel antibiotics for the treatment of drug-resistant skin infections

03 Feb 06

The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries. In exception, considerable success has been met by those targeting drug resistant infections. This is highlighted by the rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid). Here we highlight a promising early stage candidate being developed by Replidyne, REP8839
LeadDiscovery

OX40:OX40L interaction – evolving from a key component of autoimmunity to a possible target for cardiovascular disease

31 Jan 06

OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. Today we highlight additional involvement in heart disease
LeadDiscovery

Supercomputers used to go from genome to lead in under a month

25 Jan 06

Genomics and proteomics comprise a fundamental area of bioinformatics however exploiting the wealth of information gained using such disciplines remains a rate limiting step in the drug discovery process. Today’s edition of DailyUpdates (Jan 25th 2005) describes ground breaking work that has allowed researchers to identify candidate therapeutics for the treatment of SARs virus infection in under a month using the virus genome as a starting point
LeadDiscovery

BAFF & APRIL: Emerging Targets for Autoimmune & Cancer Therapeutics

18 Jan 06

In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
LeadDiscovery

Ferriprox prevents heart failure deaths in thalassaemia

16 Jan 06

A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
Olwen Glynn Owen - PharmiWeb Field Reporter

2006 –Near Term Expectations for Clinical Research

11 Jan 06

There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
Brian S. Robinson

What Future?

11 Jan 06

Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking greater career management/development and rapid progression.
Iain Jessup

The Rough Guide to Electronic Data Capture

11 Jan 06

Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Andrew Salomon

Charity = Free Job Postings!

11 Jan 06

Free Job Postings for UK Charity Organisations in the Healthcare Sector.
Mike Wood

Blog your Jobs

10 Jan 06

New Blog for Jobs
Mike Wood

Exjade - first oral treatment for iron overload - will make life easier for patients needing regular blood transfusion

22 Dec 05

New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
Olwen Glynn Owen PharmiWeb Field Reporter

Assessing the Top Four Cancer Markets

14 Dec 05

Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer, were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
Arrowhead Publishers

How to | pass personality tests

06 Dec 05

Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career.
Martin Gibbons

Dronedarone, a new anti-arrhythmic drug in development, may fill unmet need in atrial fibrillation

30 Nov 05

Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Olwen Glynn Owen - PharmiWeb Field Reporter

HIV doctors underestimate patients’ willingness to use injectables

30 Nov 05

Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Olwen Glynn Owen - PharmiWeb Field Reporter

Italy’s Renaissance for Pharma R&D

30 Nov 05

As a major pharmaceutical market, Italy is a key region for the pharmaceutical industry. In terms of value, Italy’s pharmaceutical market is the fourth largest in Europe and represents around 13% of the regional total.
Dr Faiz Kermani

Mergers Emerge in Japan

29 Nov 05

Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but recent developments show that attitudes have changed.
Dr Faiz Kermani

Mobile & Wireless Sales Force Strategies Free Report

23 Nov 05

Free Supplement on Mobile and Wireless Sales Force Strategies in Pharma - Find out how you can take advantage of the altest technologies, achieve implementation excellence and measure a ROI on sales force effeiciency!
eyeforpharma

How to | Enter the cyberspace recruitment market

22 Nov 05

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Linda Eden-Ellis

New Avian Flu Resource Page

14 Nov 05

Due to increasing interest and requests regrding the subject Pharmiweb have created a new Avian Flu resource page.
Mike Wood

Advertising